uniQure (NASDAQ:QURE) Trading 7.9% Higher – What’s Next?

Shares of uniQure N.V. (NASDAQ:QURE) rose 7.9% on Wednesday . The company traded as high as $42.00 and last traded at $39.5390. Approximately 654,926 shares were traded during mid-day trading, a decline of 74% from the average daily volume of 2,558,914 shares. The stock had previously closed at $36.66.

Wall Street Analyst Weigh In

QURE has been the subject of a number of research analyst reports. Stifel Nicolaus set a $28.00 price target on uniQure in a report on Tuesday, May 5th. Chardan Capital lifted their target price on uniQure from $31.00 to $37.00 and gave the company a “buy” rating in a research report on Thursday, April 30th. HC Wainwright boosted their target price on uniQure from $50.00 to $80.00 and gave the stock a “buy” rating in a research note on Monday, June 29th. Weiss Ratings reissued a “sell (e+)” rating on shares of uniQure in a report on Friday, June 26th. Finally, Royal Bank Of Canada raised their price target on shares of uniQure from $35.00 to $65.00 and gave the company an “outperform” rating in a research note on Thursday, June 18th. Twelve equities research analysts have rated the stock with a Buy rating, four have given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $64.17.

uniQure Stock Up 8.2%

The stock has a market capitalization of $2.50 billion, a price-to-earnings ratio of -11.46 and a beta of 0.90. The company has a quick ratio of 10.40, a current ratio of 10.40 and a debt-to-equity ratio of 0.33. The stock has a 50 day moving average price of $36.44 and a 200 day moving average price of $25.89.

uniQure (NASDAQ:QURE) last released its quarterly earnings data on Wednesday, July 29th. The biotechnology company reported ($1.22) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.82) by ($0.40). The firm had revenue of $5.84 million during the quarter, compared to analyst estimates of $5.45 million. uniQure had a negative net margin of 1,154.42% and a negative return on equity of 145.81%. During the same period in the prior year, the company earned ($0.69) EPS. As a group, analysts forecast that uniQure N.V. will post -3.39 EPS for the current year.

Insider Buying and Selling

In related news, CEO Matthew C. Kapusta sold 21,082 shares of uniQure stock in a transaction that occurred on Thursday, July 2nd. The stock was sold at an average price of $45.16, for a total value of $952,063.12. Following the transaction, the chief executive officer directly owned 519,227 shares of the company’s stock, valued at $23,448,291.32. The trade was a 3.90% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Jack Kaye sold 21,167 shares of uniQure stock in a transaction that occurred on Tuesday, June 30th. The stock was sold at an average price of $46.44, for a total value of $982,995.48. Following the completion of the transaction, the director directly owned 25,996 shares in the company, valued at approximately $1,207,254.24. This represents a 44.88% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders have sold 433,229 shares of company stock worth $17,944,799. Corporate insiders own 4.65% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the company. China Universal Asset Management Co. Ltd. boosted its stake in shares of uniQure by 5.5% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 10,150 shares of the biotechnology company’s stock valued at $243,000 after purchasing an additional 533 shares during the last quarter. Arizona State Retirement System raised its stake in uniQure by 6.0% during the fourth quarter. Arizona State Retirement System now owns 11,141 shares of the biotechnology company’s stock worth $267,000 after buying an additional 627 shares during the last quarter. Ensign Peak Advisors Inc lifted its holdings in uniQure by 21.7% in the fourth quarter. Ensign Peak Advisors Inc now owns 3,650 shares of the biotechnology company’s stock valued at $87,000 after buying an additional 650 shares during the period. CIBC Private Wealth Group LLC acquired a new position in uniQure in the third quarter valued at $50,000. Finally, Mirae Asset Global Investments Co. Ltd. boosted its position in uniQure by 42.7% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,027 shares of the biotechnology company’s stock valued at $72,000 after acquiring an additional 906 shares during the last quarter. Institutional investors own 78.83% of the company’s stock.

About uniQure

uniQure N.V. is a biotechnology company focused on the development and commercialization of gene therapies for patients with severe medical needs. Using its proprietary adeno‐associated viral (AAV) vector platform, the company designs single‐dose treatments aimed at addressing the underlying genetic causes of disease rather than solely managing symptoms. Its most advanced program, Hemgenix® (etranacogene dezaparvovec), received regulatory approval in the United States and Europe for adult patients with hemophilia B, marking one of the first gene therapies for a bleeding disorder to reach the market.

Beyond hemophilia B, uniQure’s pipeline includes preclinical and clinical-stage candidates targeting rare and debilitating conditions such as aromatic l-amino acid decarboxylase (AADC) deficiency, Huntington’s disease, and Parkinson’s disease.